N/A N=21 Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) — 1; 3; 7; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,274 Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss
Corneal Endothelial Decompensation · Fuchs' Endothelial Dystrophy
Primary: Graft Failure — 32; 15 eyes
Phase 2 N=65 Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
N/A N=40 Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
Fuchs Endothelial Dystrophy · Corneal Edema
Primary: Endothelial Cell Loss — 28; 36 percentage of endothelial cell loss — p=0.10
N/A N=129 Changes in Corneal Endothelial Cell Density After Transscleral ab Interno Glaucoma Gel Stent Implantation
Glaucoma · Endothelial Cell Loss, Corneal
Primary: Endothelial Cell Count Change — 2; -1; 0; -4 % change compared to baseline
N/A N=37 Endothelial Bleb Response With Toric Lenses
Ametropia
Primary: Endothelial Bleb Areas on Cornea: Session A- Open Eye — 0.1; 2.0; 0.2; 2.1 Percent Difference of Bleb Area
Phase 4 N=1,405 Cornea Preservation Time Study
Cornea Preservation Time · Endothelial Keratoplasty · Transplant Success
Primary: Number of Eyes With Corneal Graft Failure Within 3 Years of Surgery — 30; 49 Eyes — p=0.02
Phase 3 N=29 Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Fuchs Endothelial Dystrophy
Primary: Change in Central Corneal Thickness — -23; -2 microns
Phase 2 N=22 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Fuchs' Corneal Endothelial Dystrophy (FCED)
Primary: Incidence and Severity of Ocular TEAEs. — 3; 6; 1; 1 Participants
Phase 4 N=167 Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes
Phase 4 N=131 Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
Age-Related Macular Degeneration · Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Change From Baseline in Mean Endothelial Cell Density — -35.86 cells/millimeter squared
Phase 4 N=70 Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Corneal Endothelial Dystrophy · Corneal Edema
Primary: Immunologic Rejection — 0 Participants
Phase 2 N=264 Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)
Fuchs' Dystrophy · Bullous Keratopathy
Primary: Number of Eyes With Immunologic Graft Rejection Episodes — 2; 0 eyes — p=0.17
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
N/A N=1,090 Cornea Donor Study
Corneal Disease · Fuch's Dystrophy · Pseudophakic Corneal Edema
Primary: Graft Failure — 142; 82 participants
Phase 2 N=307 RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
Corneal Endothelial Cell Loss · Ocular Pain · Ocular Inflammation
Primary: Change From Baseline in Central Corneal Endothelial Cell Counts — -243.4; -184.8; -260.3 cells/mm^2 — p=0.4529
Phase 2 N=97 A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
Corneal Edema · Corneal Endothelial Dysfunction
Primary: Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data — 14.3; 44.4; 10.5; 36.8 Percentage of…
N/A N=657 Long Term Safety Protocol for the AcrySof CACHET Phakic Lens
Myopia
Primary: Central Endothelial Cell Density (All Eyes) — 2654.0; 2639.0; 2633.0; 2551.0 cells/mm^2
N/A N=54 Additional Long-Term Follow-up for Subjects Implanted With a CyPass® Micro-Stent
Primary Open Angle Glaucoma · Cataract
Primary: Percentage of Eyes With Sight-threatening Adverse Events (AEs) — 18.5; 0.0; 0.0; 0.0 percentage of eyes
Phase 3 N=224 DisCoVisc Comparative Evaluation
Cataracts
Primary: Percent Loss of Endothelial Cells — 9.48; 15.66; 23.69; 25.70 Percent Loss
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
Phase 4 N=184 To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
Cataract
Primary: Endothelial Cell Count Change From Baseline — -7.91; -5.11; -4.92 Percent change from baseline
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 3 N=239 Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
Progressive Keratoconus
Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
N/A N=55 Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®
Cataract
Primary: Cumulative Dissipated Energy (CDE) — 0.213; 1.718 unitless — p=<0.0001
N/A N=135 Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
Keratoconus
Primary: Number of Participants With Complete Healing of Corneal Epithelial Defect at Day 3 — 20; 25 Participants
Phase 3 N=130 Corneal Collagen Cross-Linking for Ectasia (CXL)
Ectasia
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -0.5; 0.5 diopters
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal